BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

- CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is...

Related Keywords

United States ,Israel ,Israeli ,Bio Pharma ,Che Bio ,Neil Kumar ,Michael Hercz ,Linkedin ,Twitter ,Zydus Group ,Bridgebio Pharma Inc ,European Union ,Securities Exchange ,Bio Pharma Inc ,Israeli Ministry Of Health ,Israeli Ministry ,Matt Heck ,New Drug Application ,Molybdenum Cofactor Deficiency ,Bridgebio Pharma ,Securities Act ,Securities Exchange Act ,Exchange Act ,Risk Factors ,Annual Report ,Bio Contact ,Therapeutics Contact ,Sentynl Therapeutics ,